Hans Clevers

Hans Clevers pioneered organoid technology by discovering that single Lgr5-positive stem cells can generate self-organizing three-dimensional mini-organs in culture, a breakthrough that has transformed cancer research by enabling growth of patient-derived tumor organoids that faithfully recapitulate the histology, genomics, and drug response of the original tumor. His laboratory established the first living tumor organoid biobanks for colorectal, pancreatic, breast, and other cancer types, providing renewable patient-derived models for personalized drug screening. He has demonstrated that organoid drug sensitivity testing can predict clinical treatment outcomes. His organoid technology is now being integrated with organ-on-chip systems for more physiological cancer modeling.